Edward J Frech

  • Citations Per Year
Learn More
OBJECTIVES Treatment for gastrointestinal tract (GIT) disease in systemic sclerosis (SSc) is challenging as no immunosuppressive or anti-fibrotic therapy is available with clearly proven efficacy. Probiotics are viable, non-pathogenic microorganisms that are hypothesized to improve the composition of the intestinal microbiota from a potentially harmful(More)
Mechanical obstruction is common in advanced gastrointestinal malignancies and may be associated with significant morbidity. Patients with malignant bowel obstruction are often poor surgical candidates due to advanced disease, malnutrition, hypoalbuminemia, and dehydration. Recent advances in endoscopy have led to a variety of highly efficacious,(More)
BACKGROUND Direct percutaneous endoscopic jejunostomy (DPEJ) is a well-known approach to deliver postpyloric enteral nutrition support to individuals who cannot tolerate gastric feeding. DPEJ addresses many of the shortcomings of jejunal feeding tubes placed through percutaneous endoscopic gastrostomy tubes. The safety and efficacy of DPEJ in adults has(More)
Pruritus is a common symptom in systemic sclerosis (SSc), an autoimmune disease which causes fibrosis and vasculopathy in skin, lung, and gastrointestinal tract (GIT). Unfortunately, pruritus has limited treatment options in this disease. Pilot trials of low-dose naltrexone hydrochloride (LDN) for pruritus, pain, and quality of life (QOL) in other GIT(More)
  • 1